Warner Chilcott Plc (NASDAQ: WCRX) shares fell 1.6% to begin Thursday at $14.35. The company announced this week that the United States Food and Drug Administration has approved its new 400 mg mesalamine product indicated for the treatment of ulcerative colitis. The Company anticipates that it will commercially launch DELZICOL in March 2013. Share volume was 1.2 million, compared to an all-day average of 4.9 million